Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Immunic Analyst Ratings and Price Targets | NASDAQ:IMUX | Benzinga
Immunic Inc has a consensus price target of $15.09 based on the ratings of 12 analysts. The high is $35 issued by Aegis Capital on August 8, 2022. The low is $5 issued by Leerink Partners on September 9, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital, HC Wainwright & Co., and D. Boral Capital on February 26, 2025, February 21, 2025, and February 20, 2025, respectively. With an average price target of $14.67 between D. Boral Capital, HC Wainwright & Co., and D. Boral Capital, there's an implied 1112.12% upside for Immunic Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
EF Hutton
Leerink Partners
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Immunic
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | — | William Blair | Myles Minter43% | — | Initiates | → Outperform | Get Alert |
| 02/26/2025 | Buy Now | 1304.96% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 726.45% | HC Wainwright & Co. | Matthew Caufield37% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 1304.96% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 1304.96% | D. Boral Capital | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 726.45% | HC Wainwright & Co. | Matthew Caufield37% | → $10 | Initiates | → Buy | Get Alert |
| 11/07/2024 | Buy Now | 1304.96% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | 1304.96% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | 1304.96% | EF Hutton | Jason Kolbert46% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/16/2024 | Buy Now | 1304.96% | EF Hutton | Jason Kolbert46% | → $17 | Initiates | → Buy | Get Alert |
| 09/09/2024 | Buy Now | 313.22% | Leerink Partners | Faisal Khurshid29% | → $5 | Assumes | → Outperform | Get Alert |
| 08/27/2024 | Buy Now | 395.87% | B. Riley Securities | William Woods23% | → $6 | Initiates | → Buy | Get Alert |
| 07/16/2024 | Buy Now | 2214.05% | Piper Sandler | Yasmeen Rahimi59% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 726.45% | Brookline Capital | Tyler Bussian23% | → $10 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 478.51% | Wedbush | Andreas Argyrides68% | $5 → $7 | Maintains | Outperform | Get Alert |
| 07/27/2023 | Buy Now | 313.22% | Wedbush | Andreas Argyrides68% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 01/31/2023 | Buy Now | 313.22% | Wedbush | Andreas Argyrides68% | → $5 | Assumes | → Outperform | Get Alert |
| 10/21/2022 | Buy Now | 313.22% | SVB Leerink | Thomas Smith33% | $9 → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2022 | Buy Now | 2048.76% | HC Wainwright & Co. | Gobind Singh20% | → $26 | Assumes | → Buy | Get Alert |
| 08/08/2022 | Buy Now | 2792.56% | Aegis Capital | Nathan Weinstein31% | $40 → $35 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 643.8% | SVB Leerink | Thomas Smith33% | $45 → $9 | Maintains | Outperform | Get Alert |
| 05/18/2022 | Buy Now | 3123.14% | Piper Sandler | Yasmeen Rahimi59% | $71 → $39 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Immunic (IMUX) stock?
The latest price target for Immunic (NASDAQ:IMUX) was reported by William Blair on March 25, 2025. The analyst firm set a price target for $0.00 expecting IMUX to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunic (IMUX)?
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by William Blair, and Immunic initiated their outperform rating.
When was the last upgrade for Immunic (IMUX)?
There is no last upgrade for Immunic
When was the last downgrade for Immunic (IMUX)?
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Immunic (IMUX) correct?
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a initiated with a price target of $0.00 to $0.00. The current price Immunic (IMUX) is trading at is $1.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.